Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.
The AE37 immunotherapeutic vaccine is being developed by Antigen Express, Generex's wholly-owned subsidiary, for use in patients with HER2 positive cancers:
- The vaccine is the subject of a randomized and controlled Phase II trial in patients with breast cancer; positive interim results, showing reduced relapse rates in patients receiving AE37, were released late in 2009.
- A Phase I trial of AE37 in patients with prostate cancer has been completed recently.
- A Phase I trial of AE37 in combination with another peptide vaccine is underway in patients with breast or ovarian cancer.
Thrombotic thrombocytopenic purpura cases after CoronaVac raise concerns over vaccine safety